NASDAQ OMX

Synechron Will Launch Blockchain Applications on the Microsoft Azure Marketplace

22.5.2017 16:01 | NASDAQ OMX

Dela

Synechron's trade finance application is the first publicly available blockchain application on JP Morgan's Quorum platform

NEW YORK, LONDON, PARIS, AMSTERDAM, DUBAI, PUNE, India and SINGAPORE, May 22, 2017 (GLOBE NEWSWIRE) -- Synechron Inc., the global financial services consulting and technology services provider, has today announced that demo versions of a select group of its blockchain accelerator applications will be made available on Microsoft Azure. These include the Blockchain Accelerator for Trade Finance now available on Quorum, the Blockchain Accelerator for Insurance Claims Processing on Ethereum, and the Blockchain Accelerator for Smart Margin Calls now available on Corda. This makes Synechron's Trade Finance Accelerator one of the first publicly viewable application to use the Quorum platform, demonstrating its Constellation and Enclave functionality for bank-driven requirements. These Accelerators will be available on Azure the week of May 22 and are currently available for a live demo at Consensus 2017 in New York, May 22-24.

Synechron, working in conjunction with the Microsoft Azure Blockchain team, are pleased to announce the general demo availability of three new Blockchain Accelerators on the Azure Marketplace. The Accelerators are industry-leading and award-winning applications that focus on six industry use cases: Trade Finance, KYC, Margin Call Management, Insurance Claims Processing, Mortgage Financing & Processing, and Global Payments. These solutions extend leading ledger platforms including Ethereum, Quorum, Hyperledger's Fabric, Corda, and Ripple. Synechron's Blockchain Accelerators can be rapidly deployed into the Microsoft cloud by anyone with an Azure subscription, making it easy for clients to choose a cloud-based deployment model with enterprise security in mind.

Marley Gray, Principal Architect for Azure Blockchain said, "Microsoft is building an open, ecosystem-driven platform for blockchain app development. Through partners like Synechron, we're empowering businesses to accelerate their own blockchain initiatives. We're excited to offer these three Accelerators, which show customers what blockchain applications could potentially look like."

Faisal Husain, Synechron CEO, said: "Developing innovative, real-world solutions drives everything we do, so being the first company to share working blockchain applications on Azure is incredibly significant for us. This week, users will be able to see how a blockchain really works and experience the different functionalities available across platforms. We have no doubt that this will help stimulate further interest in the potential of blockchain, enabling financial services firms to accelerate their blockchain initiatives."

More information these three blockchain applications from Synechron can be found below:

  1. Blockchain Accelerator for Trade Finance - creates digital versions of transactions, generates smart contracts, centralises underlying collateral information on a distributed ledger across a private network to increase efficiency, eliminates "double spend" fraud, enhances data quality and reduces settlement time.
     
  2. Blockchain Accelerator for Smart Margin Calls - uses smart contracts to determine the valuation of the trade portfolio, handles margin calls and initiates track and validates margin payments for increased efficiency, automated settlements, enhanced accuracy and significant cost-reduction. 
     
  3. Blockchain Accelerator for Insurance Claims Processing - uses smart contracts, enables auto-execution of insurance claims and payments on an authoritative data feed for reduced risk and fraud and decreased processing costs.

For more information:
For more information on Synechron's Blockchain Accelerator Program go to our website at www.synechron.com/finlabs.

About Synechron

Synechron is a global consulting and technology organization providing innovative solutions to the financial services industry through its three main business focus areas: digital, business consulting, and technology. Based in New York, the company has 18 offices around the globe, with over 7,500+ employees producing over $450+M in annual revenue. For more information on the Company please visit the website or our LinkedIn community.

For further information, please contact:

Synechron 
Diana Kearns-Manolatos 
Synechron, Inc.
Diana.Kearns@synechron.com 
m: 1 347-721-8223

UK
Dan Williams
Rostrum
+44 (0)203 727 3740
dan.williams@rostrumpr.com

India
Rajesh Joshi (for Synechron enquires)
The Good Edge
rajesh@thegoodedge.com
m: +91 9833171525




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Synechron via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Scientific breakthrough on objective diagnosis of PTSD26.6.2017 16:51Pressmeddelande

Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide rights to commercialise the technology SYDNEY, Australia and MINNEAPOLIS, June 26, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange-listed medical technology company Medibio Limited (MEB or the Company) announces a new research study, conducted at Emory University, Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress disorder (PTSD) can be accurately diagnosed using a non-invasive protocol involving heart rate data and machine learning algorithms. The research was based on technology developed at Emory University and licensed by Medibio. The research is described in a paper titled "Classification of post-traumatic stress disorder from heart rate vari

Informa's Annual Clinical and Research Excellence Awards Return for Third Year26.6.2017 16:48Pressmeddelande

BOSTON, June 26, 2017 (GLOBE NEWSWIRE) -- Informa's Pharma Intelligence has today announced that the third annual Clinical and Research Excellence (CARE) Awards are now open for nominations. Pharma Intelligence - the world's leading provider of clinical and research intelligence and analysis, and home of leading brands such as Scrip, Pink Sheet and Biomedtracker - will host the awards which recognize and celebrate outstanding achievements and stand-out performers in the global R&D space. Nominations for the CARE Awards are free and all submissions should be made via the online entry form available at www.clinicalresearchexcellence.com by December 23. All entries will be assessed by a panel of distinguished industry experts and the winners will be announced at the CARE Awards ceremony on April 25, 2018 at the Boston Harbor Hotel. "The success of last year's CARE Awards was testament to the original mission of the CARE Awards: to recognize the ex

Forterra Announces Definitive Agreement with Thompson Pipe Group26.6.2017 14:00Pressmeddelande

Thompson Pipe Group to Acquire Forterra's U.S. Concrete and Steel Pressure Pipe Assets Forterra to Acquire Thompson Pipe's Drainage Pipe & Products Manufacturing Facility with a Strategic Position in Houston Market IRVING, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra" or the "Company") (Nasdaq:FRTA), a leading manufacturer of water infrastructure pipe and products in the United States and Eastern Canada, today announced it has entered into a definitive agreement to sell the U.S. concrete and steel pressure pipe assets of its Water Pipe and Products business segment to Thompson Pipe Group. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2017.  Under the terms of the agreement, an affiliate of Thompson Pipe Group will acquire assets related to five Forterra manufacturing facilities and a fittings facility. Forterra will receive approximate

Nasdaq Closing Cross Calculates Russell US Indexes Reconstitution for the 14th Consecutive Year24.6.2017 01:52Pressmeddelande

A new record $28.9 billion traded at the closing cross in a Russell reconstitution NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Symbol: NDAQ) today announced the Nasdaq Closing Cross was used for the 14th consecutive year to rebalance Nasdaq-listed securities in the entire family of  Russell US Indexes, part of leading global index provider FTSE Russell, during its annual reconstitution. More than 972 million shares representing a record $28.9 billion were executed in the Nasdaq Closing Cross in 0.861 seconds across some 2,499 Nasdaq-listed stocks. The previous record for dollars traded at the closing cross in a Russell reconstitution was $21.1 billion in 2015. "For the 14th consecutive year of partnering with FTSE Russell on the rebalance, we witnessed the advanced capabilities and market integrity of Nasdaq's INET technology platform resulting in transparent and efficient price discovery which benefits issuers and investors alike,&quot

LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52Pressmeddelande

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci

Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00Pressmeddelande

6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future.  Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum